OutPerformDaily

  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks

Lost Password?

Top 3 AI Stocks to Invest in Right Now

Fake shopping sprees and ‘happiness insurance’: The latest fintech apps reveal our financial anxieties

Is Apple’s foldable iPhone Duo worth $2,000? See how it stacks up against other foldable phones.

I gave my HomeExchange guest a 5-star review. Then I found heat marks all over my dining table. Do I call her out?

Inside the push to weaken Washington’s toughest financial watchdog

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
3rdPartyFeeds

Apple’s killer quarter buys more time for the company to deliver clarity on AI

July 31, 2025

The stock remains an AI "show me" story. Read more...

3rdPartyFeeds

Why we’re keeping our buy rating on Amazon — even as shares tumble after earnings

July 31, 2025

The market will nitpick a couple of areas in the quarter over the next few days, but the thesis on Amazon is unchanged. Read more...

3rdPartyFeeds

Reddit shares jump as much as 20% on second-quarter sales and guidance beat

July 31, 2025

The company's revenue grew 78% year-over-year in the second quarter and was 17% above consensus estimates, the biggest beat in Reddit's history. Read more...

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors
Uncategorized

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

July 31, 2025

Novo Nordisk announced today that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci) injection as a once-daily prophylaxis to prevent...

3rdPartyFeeds

Coinbase shares tumble as second-quarter revenue disappoints

July 31, 2025

Subscription revenue failed to offset weaker trading revenue. Read more...

3rdPartyFeeds

Roblox stock soars 10% after revenue beat, strong user growth

July 31, 2025

User and engagement numbers were also strong for gaming platform Roblox, with daily active users up 41% year over year, and hours engaged up 58%. Read more...

3rdPartyFeeds

Amazon earnings primer: Why AI and tariffs are key to the second quarter

July 31, 2025

The earnings report will give investors a fresh look at how Amazon is navigating tariff-related uncertainty. Read more...

3rdPartyFeeds

We’re lowering our price target on Bristol Myers as two key overhangs persist

July 31, 2025

Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter. Read more...

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)
Uncategorized

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

July 31, 2025

The Dow Jones index rose Thursday as it appeared a China trade deal was near. Nvidia partner Arm plunged on earnings.

3rdPartyFeeds

CVS shares pop on earnings beat and outlook, as retail pharmacy and insurance units improve

July 31, 2025

CVS CEO David Joyner pointed to strength in its retail pharmacy and improvement in its insurance unit, Aetna, which is grappling with higher medical costs...

Previous 1 … 133 134 135 136 137 … 8,455 Next
Indices by TradingView

Categories

  • 3rdPartyFeeds
  • Cannabis Stocks
  • Index Funds
  • International
  • News
  • Short
  • Stock Picks
  • Tech Stocks
  • Uncategorized
Indices by TradingView
While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.